True behavior of the 'pleasure molecule' will reshape treatment of psychiatric diseases and addiction

True behavior of the 'pleasure molecule' will reshape how we treat psychiatric diseases and addiction
Figure 1. Dopamine in the nucleus accumbens core does not track reward prediction error in negative reinforcement tasks (A) Positive reinforcement task. (B) Dopamine was recorded via fiber photometry using dLight1.1. (C) Mice made more active than inactive responses during the post-training session (t6 = 3.18, p = 0.024; n = 6). (D and E) Heatmaps showing dopamine responses aligned around Sd,sucrose (left) and head entry (right) during (D) pre-training and (E) post-training. Each row represents a single Sd,sucrose presentation or head entry. (F and G) Averaged traces showing Sd,sucrose (F) and (G) head entry responses during pre- and post-training. (H) Dopamine increased to the Sd,sucrose (F1,153 = 10.79, p = 0.0013) and decreased to head entries over training (F1,75 = 11.17, p = 0.0013). (I) Negative reinforcement task. (J) Fiber photometry recording design. (K) Behavioral performance during negative reinforcement post-training session (t4 = 9.35, p < 0.001; n = 5). (L and M) Heatmaps of dopamine responses aligned around Sd,shock (left), footshock (center), and safety cue (right) during pre-training (L) and (M) post-training. (N–P) Dopamine traces to Sd,shock (N), (O) safety cue, and (P) footshock pre- and post-training. (Q) Dopamine response to Sd,shock (F1,96 = 1.52, p = 0.220), footshock (F1,127 = 4.00, p = 0.047), and safety cues (F1,95 = 15.46, p = 0.0002). Error bars represent ± S.E.M. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Credit: DOI: 10.1016/j.cub.2021.08.052

Pioneering research shows that dopamine levels increase in response to stressful stimuli, and not just pleasurable ones, potentially rewriting facts about the "feel-good" hormone—a critical mediator of many psychiatric diseases. This discovery is cause to rethink treatment for psychiatric disease and addiction.

This research was led by Erin Calipari and Cody Siciliano, both assistant professors of pharmacology, and Munir Gunes Kutlu, a postdoctoral fellow in Calipari's laboratory.

"In the press, is often referred to as a 'pleasure molecule' or a 'reward molecule,'" said Calipari, who also is a faculty member of the Vanderbilt Brain Institute and the Center for Addiction Research. "In the , research has helped us understand that dopamine's role in learning and memory is more complex than that, but we did not have a complete and accurate theory that could explain what dopamine actually does in the brain."

The prevailing model, called the reward prediction error theory, is based on the idea that dopamine signals predictions about when rewards will occur. This theory suggests that dopamine is a tracker of every error we make when we try to achieve rewards. The authors show that RPE is only accurate in a subset of learning scenarios by proving that "while rewards increase dopamine, so do stressful stimuli," Calipari said. "We then go on to show that dopamine is not a reward molecule at all. It instead helps encode information about all types of important and relevant events and drive adaptive behavior—regardless of whether it is positive or negative."

The researchers collaborated with Lin Tian, professor and vice chair of biochemistry and at UC Davis, to use cutting-edge technology to study an unprecedented diversity of neurobehavioral processes related to dopamine release. The authors used machine learning and computational modeling to analyze the data, along with optogenetic manipulations, which use light to control activity of genetically modified neurons.

The analysis established a novel computational model of behavior that shows "accurate prediction of the behavioral impact of optogenetic perturbations of dopamine release." Calipari concluded that "this work replaces our current understanding with a formalized theory and calls for revision of textbook facts regarding dopamine in the central nervous system."

Credit: Vanderbilt University

Why it matters

"A common theme of all drugs of abuse is that they increase dopamine release in the brain, which helped feed the notion of dopamine as a reward molecule. This work clearly demonstrates a much more sophisticated role for this neurotransmitter, and it means we need to rethink models of that depend on the dopamine/drug reward mentality," said Danny Winder, director of the Vanderbilt Center for Addiction Research.

Calipari emphasizes that "these data rewrite facts about dopamine, including what it encodes within the brain and how it drives behavior." This is incredibly important as dopamine is dysregulated in Parkinson's disease and in nearly every psychiatric disease: addiction, anxiety and depression, schizophrenia and others, she said. Understanding what these dopamine deficits mean will be critical in understanding patients' symptoms and in developing better evidence-based treatments for these diseases.

What's next?

"We plan to research how this framework fits into our understanding of drug addiction and how drugs alter dopamine signaling to disrupt behavior within this novel framework," Calipari said. "Most of our understanding of addiction neurobiology centers around dopamine and the dopaminergic network, as many therapeutic approaches that aim to treat addiction target dopamine. However, altering dopamine without having a full understanding of what dopamine actually does may lead to many unforeseen side effects, and more importantly, failed treatment strategies. This new knowledge about what dopamine actually does will affect many fields outside neuroscience and have a strong impact on human lives and health outcomes."

The article, "Dopamine release in the nucleus accumbens core signals perceived saliency," was published in the journal Current Biology on Sept. 15.

More information: Munir Gunes Kutlu et al, Dopamine release in the nucleus accumbens core signals perceived saliency, Current Biology (2021). DOI: 10.1016/j.cub.2021.08.052

Journal information: Current Biology

Citation: True behavior of the 'pleasure molecule' will reshape treatment of psychiatric diseases and addiction (2021, September 16) retrieved 2 October 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Research with dopamine in mice challenging theories of reward and learning


Feedback to editors